31P nuclear magnetic resonance spectroscopy: A noninvasive tool to monitor metabolic abnormalities in left ventricular hypertrophy in humans

American Journal of Cardiology

Volumn 83, Issue 12 A, 1999, Pages 19-24

  Jung, Wulf Ingo ^b   Dietze, Guenther J ^a  

^a Max Grundig Clinic   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AORTA STENOSIS; AORTA VALVE REGURGITATION; CONFERENCE PAPER; CYCLING; DIALYSIS; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE METABOLISM; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; MITRAL VALVE REGURGITATION; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; ENERGY METABOLISM; HEART MUSCLE; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; REPRODUCIBILITY; REVIEW;

ADENOSINE TRIPHOSPHATE; PHOSPHATASE; PHOSPHATE; PHOSPHORUS;

ADENOSINE TRIPHOSPHATE; ENERGY METABOLISM; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MAGNETIC RESONANCE SPECTROSCOPY; MYOCARDIUM; PHOSPHATES; PHOSPHORIC MONOESTER HYDROLASES; PHOSPHORUS ISOTOPES; REPRODUCIBILITY OF RESULTS;

EID: 0033577914     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00252-0     Document Type: Conference Paper

References (46)

1. Levy D., Garrison R.J., Savage D.D., Kannel W.B., Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med. 322:1990;1561-1566.
2. Koren M., Deverux R.B., Laragh J.H. Relation of left ventricular mass and geometry to morbidity in uncomplicated essential hypertension. Ann Intern Med. 114:1991;3345-3352.
3. McKenna W.J., Camm A.J. Sudden death in hypertrophic cardiomyopathy assessment of patients at high risk . Circulation. 80:1989;1489-1492.
4. Drory Y., Turetz Y., Hiss Y., Lev B., Fisman E.Z., Pines A., Kramer M.R. Sudden unexpected death in persons <40 years of age. Am J Cardiol. 68:1991;1388-1392.
5. 31P magnetic resonance spectroscopy using the rotating frame-depth selection technique. Ann N Y Acad Sci. 508:1987;321-332.
6. Weiss R.G., Bottomley P.A., Hardy C.J., Gerstenblith G. Regional myocardial metabolism of high-energy phosphates during isometric exercise in patients with coronary artery disease. N Engl J Med. 323:1990;1593-1600.
7. Masuda Y., Tateno Y., Ikehira H., Hashimoto T., Shishido F., Sekiya M., Imazeki Y., Imai H., Watanabe S., Inagaki Y. High-energy phosphate metabolism of the myocardium in normal subjects and patients with various cardiomyopathies the study using ECG gated MR spectroscopy with a localization technique . Jpn Circ J. 56:1992;620-626.
8. de Roos A., Doornbos J., Luyten P.R., Oosterwaal L.J.M.P., van der Wall E.E., den Hollander J.A. Cardiac metabolism in patients with dilated and hypertrophic cardiomyopathy assessment with proton-decoupled P-31 MR spectroscopy . J Magn Reson Imaging. 2:1992;711-719.
9. 31P MR spectroscopy in hypertrophic cardiomyopathy comparison with Tl-201 myocardial perfusion imaging . Am Heart J. 125:1993;1323-1328.
10. 31P NMR spectra of the myocardium of patients with myocardial hypertrophy. J Magn Reson. 133:1998;232-235.
11. 31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Circulation. 97:1998;2536-2542.
12. 31P MRS . Magn Reson Med. 39:1998;772-782.
13. Schaefer S., Gober J.R., Schwartz G.G., Twieg D.B., Weiner M.W., Massie B. In vivo phosphorus-31 spectroscopic imaging in patients with global myocardial disease. Am J Cardiol. 65:1990;1154-1161.
14. 31P magnetic resonance spectroscopy. Lancet. 338:1991;973-976.
15. 31P-magnetic resonance spectroscopy. J Invest Med. 45:1997;453-462.
16. Conway M.A., Bottomley P.A., Ouwerkerk R., Radda G.K., Rajagopalan B. Mitral regurgitation. Impaired systolic function, eccentric hypertrophy, and increased severity are linked to lower phosphocreatine/ATP ratios in humans. Circulation. 97:1998;1716-1723.
17. Tagami T., Sakuma H., Matsumara K., Takeda K., Mori S., Takuchi T., Nakano T. Evaluation of altered myocardial high energy phosphate metabolism in patients on maintenance dialysis using phosphorus-31 magnetic resonance spectroscopy. Invest Radiol. 33:1998;171-176.
18. Pluim B.M., Chin J.C., de Roos A., Doornbos J., Siebelink H.M.J., van der Laarse A., Vliegen H.W., Lamerichs R.M.J.N., Bruschke A.V.G., van der Wall E.E. Cardiac anatomy, function and metabolism in elite cyclists assessed by magnetic resonance imaging and spectroscopy. Eur Heart J. 17:1996;1271-1278.
19. Pluim B.M., Lamb H.J., Kayser H.W.M., Leujes F., Beyerbacht H.P., Zwinderman A.H., van der Laarse A., Vliegen H.W., de Roos A., Doornbos J., van der Waal E.E. Functional and metabolic evaluation of the athlete's heart by magnetic resonance imaging and dobutamine stress magnetic resonance spectroscopy. Circulation. 97:1998;666-672.
20. Brown T.R., Kincaid B.M., Urgubil K. NMR chemical shift imaging in three dimensions. Proc Natl Acad Sci USA. 79:1982;3523-3526.
21. 31P NMR spectroscopy. Science. 229:1985;769-772.
22. Ordidge R.J., Connelly A., Lohman J.A.B. Image-selected in vivo spectroscopy (ISIS) a new technique for spatially selective NMR spectroscopy . J Magn Reson. 66:1986;283-294.
23. 31P nuclear magnetic resonance spectroscopy. Neurology. 35:1985;781-788.
24. 31P-NMR spectroscopy of human blood and serum first results from volunteers and patients with congestive heart failure, diabetes mellitus and hyperlipidaemia . MAGMA. 1:1993;55-60.
25. 31P NMR spectroscopy. NMR Biomed. 1:1989;177-183.
26. Noggle J.H., Schirmer R.E. The Nuclear Overhauser Effect. 1971;Academic Press, New York.
27. Bottomley P.A. MR spectroscopy of the human heart the status and the challenges . Radiology. 191:1994;593-612.
28. Brush J.E. Jr, Eisenhofer G., Garty M., Stull R., Maron B.J., Cannon R.O. III, Panza J.A., Epstein S.E., Goldstein D.S. Cardiac norepinephrine kinetics in hypertrophic cardiomyopathy. Circulation. 79:1989;836-844.
29. Tarazi R.C., Sen S., Saragoca M., Khairallah P. The multifactorial role of catecholamines in hypertensive cardiac hypertrophy. Eur Heart J. 3:(suppl A):1982;103-110.
30. Goodwin G.W., Ahmad F., Taegtmeyer H. Preferential oxidation of glycogen in isolated working rat heart. J Clin Invest. 97:1996;1409-1416.
31. Balaban R.S. Regulation of oxidative phosphorylation in the mammalian cell. Am J Physiol. 258:1990;C377-C389.
32. Conway M.A., Bristow J.D., Blackledge M.J., Rajagopalan B., Radda G.K. Cardiac metabolism during exercise measured by magnetic resonance spectroscopy. Lancet. 2:1988;692.
33. Schaefer S., Schwartz G.G., Gober J.R., Wong A.K., Camacho S.A., Massie B., Weiner M.W. Relationship between myocardial metabolites and contractile abnormalities during graded regional ischemia. J Clin Invest. 85:1990;706-713.
34. Allard M.F., Henning S.L., Wambolt R.B., Granleese S.R., English D.R., Lopaschuk G.D. Glycogen metabolism in the aerobic hypertrophied rat heart. Circulation. 96:1997;676-682.
35. Tanaka M., Fujiwara H., Onodera T., Wu D.J., Matsuda M., Hamashima Y., Kawai C. Quantitative analysis of narrowings of intramyocardial small arteries in normal hearts, hypertensive hearts, and hearts with hypertrophic cardiomyopathy. Circulation. 75:1987;1130-1139.
36. Rakusan K., Flanagan M.F., Geva T., Southern J., van Praagh R. Morphometry of human capillaries during normal growth and the effect of age in left ventricular pressure-overload hypertrophy. Circulation. 86:1992;38-46.
37. Maron B.J. Hypertrophic cardiomyopathy. Curr Probl Cardiol. 18:1993;639-704.
38. Maron B.J., Epstein S.E., Roberts W.C. Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary arteries. Am J Cardiol. 43:1979;1086-1102.
39. Camici P., Chiaretti G., Lorenzoni R., Bellina R.C., Gistri R., Italiani G., Parodi O., Salvadori P.A., Nista N., Papi L., L'Abbate A. Coronary vasodilatation is impaired in both hypertrophied and non-hypertrophied myocardium of patients with hypertrophic cardiomyopathy a study with nitrogen-13 ammonia and positron tomography . J Am Coll Cardiol. 17:1991;879-886.
40. O'Gara P.T., Bonow R.O., Maron B.J., Damske B.A., van Lingen A., Bacharach S.L., Larson S.M., Epstein S.E. Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy assessment with thallium-201 emission computed tomography . Circulation. 76:1987;1214-1223.
41. 123I-labeled fatty acids in nonischemic myocardial diseases. Nuklearmedizin. 27:1988;72-78.
42. 31P magnetic resonance spectroscopy of the Sherpa heart a phosphocreatine/adenosine triphosphate signature of metabolic defense against hypobaric hypoxia . Proc Natl Acad Sci USA. 93:1996;1215-1220.
43. Taegtmeyer H. Myocardial metabolism. Phelphs M., Mazziotta J., Schelbert H. Positron Emission Tomography Principles and Applications for Brain and Heart . 1986;149-195 Raven Press, New York.
44. Ingwall J.S. Is cardiac failure a consequence of decreased energy reserve? Circulation. 87:(suppl VII):1993;VII-58-VII-62.
45. Zhang J., Zhang Y., Murakami Y., From A.H., Ugurbil K., Bache R.J. Myocardial oxygenation and bioenergetics at high work states in hearts with left ventricular hypertrophy. (Abstr.) Circulation. 96:(suppl I):1997;1413.
46. 403/+ mouse model of familial hypertrophic cardiomyopathy. J Clin Invest. 101:1998;1775-1783.